Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.65 |
| ▸ | NR4A2 | P43354 | 6/20 | 0.56 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520384 | 0.88 | NR4A2 (0.71) | MRGPRX4NR4A2GPBAR1RAB9ANR4A1 | |
| SCHEMBL1426961 | 0.85 | MEN1 (1.00) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| Hydrochloric Acid SCHEMBL6841086 | 0.83 | MEN1 (0.96) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| SCHEMBL4265977 | 0.82 | MRGPRX4 (0.56) | MEN1KMT2AMRGPRX4NR4A2RAB9A | |
| SCHEMBL862870 | 0.82 | MEN1 (0.93) | MEN1KMT2AMRGPRX4NR4A2NR4A1 | |
| SCHEMBL31141980 | 0.81 | MEN1 (0.79) | MEN1KMT2ANR4A2RAB9ANR4A1 | |
| SCHEMBL3599480 | 0.81 | MEN1 (0.79) | MEN1KMT2ANR4A2RAB9ANR4A1 | |
| SCHEMBL2570286 | 0.81 | MEN1 (0.84) | MEN1KMT2AMRGPRX4NR4A2GPBAR1 | |
| SCHEMBL9370131 | 0.80 | CASP3 (0.51) | MEN1KMT2ANPC1MAPTCYSLTR1 | |
| SCHEMBL8994871 | 0.79 | RAB9A (0.67) | MRGPRX4RAB9ACYSLTR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-4248997-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR COVID-19 | Hiroshima University (JP) | 2023-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | PIN1, ACE2, ACE | MEN1 3457/4885KMT2A 3733/4885MRGPRX4 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.